WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 43'0801 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 38'8511 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 64'641  64'291  63'937  63'582  63'231  59'213  56'846  53'941 
Births 793  792  792  791  791  757  756  757 
Surviving infants 790  789  789  789  789  753  750  749 
Pop. less than 5 years 3'960  3'943  3'924  3'906  3'895  3'668  3'809  3'422 
Pop. less than 15 years 11'739  11'716  11'684  11'646  11'605  11'215  11'281  12'043 
Female 15-49 years 14'292  14'328  14'360  14'390  14'421  14'510  14'346  13'055 

Number of reported case

(Click for retrospective incidence data for France)
Diphtheria
Japanese encephalitis
Measles 267  272  14'949  5'048  10'000  1'244 
Mumps 17'400 
Pertussis 165  100 
Polio* 10 
Rubella
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)** 10  14  26  33  208 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for France)
Vaccine year result method % card seen                                                
BCG          78  83  74 
DTP1          99  99 
DTP3          99  99  99  99  99  97  94 
DTP4          92 
IPV1         
HepB_BD         
HepB3          78  74  78  74  65  26 
Hib3          98  98  98  98  97  86 
JapEnc         
MCV1          91  89  91  89  89  84  71 
MCV2          72  67  72  67 
PCV1          95  95  96 
PCV3          89  89  89  86  89 
Pol3          99  99  99  99  99  98  95 
Rota1         
Rota_last          56 
Rubella1          91  89  91  90 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for France)
BCG 83  74  80 
DTP1 99  99  99  99  99  99  97  92 
DTP3 99  99  99  99  99  97  94  79 
HepB3 82  74  78  74  65  26 
HepB_BD
Hib3 98  98  98  98  97  86 
MCV1 90  89  90  89  89  84  71 
MCV2 74  67  72  67  70 
PCV3 89  89  89  89  89 
Pol3 99  99  99  99  99  98  95  80 
Rota_last

Number of districts in the country 101  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 0
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes Infant at risk
DTaPHibHepIPV 2, 4, 11 months; Yes
DTaPIPV 6 years; Yes
HPV 11-14 years (x2 doses); Yes Girls
Influenza_Adult Yes elderly, pregnant women, health care workers, adults with chronic disease and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MMR 12, 16-18 months; Yes
MenC_conj 12 months; Yes
Pneumo_conj 2, 4, 11 months; Yes
Pneumo_ps > 2 years; Yes population at risk
TdaPIPV 11-13 years; Yes
Varicella 12-18 years; If no disease history . For specific at risk-groups only. 2 doses
YF 12 months, No French Guyana

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  No  No   
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 101  101  101  101  100  100  100 
Nº districts with DTP3 coverage >=80% number 89 
% of districts with DTP3 coverage >=80% From 0 to 100% 88 
Nº districts with measles (MCV1) coverage >=95% number           NA 
% of districts with MCV1 coverage >=95% From 0 to 100%          

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes         
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  No  No    Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.